Filing Flows › Health Care › Dogwood Therapeutics (DWTX)
Dogwood Therapeutics (DWTX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Dogwood Therapeutics (DWTX) Q3 2026 earnings results →
Dogwood Therapeutics made $100K in Q3 2026. Operating margin n/m, net loss $4.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $100K in Q3 2026.
Gross margin was 11.9%. Operating costs exceeded revenue by $4.9M, an operating margin of -4917.3%. The quarter ended with a net loss of $4.9M.
Operating cash flow was −$4.6M. Non-cash charges added back $558K of share-based compensation. Working capital and other items used $312K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $100K | — | n/m | −$4.9M | −$4.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Dogwood Therapeutics
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc. (“Pharmagesic”) and their wholly owned subsidiary, Wex Pharmaceuticals, Inc. (“Wex”), and Wex’s wholly owned subsidiaries, IWT Bio, Inc. (“IWT”), Wex Medical Corporation (“WMC”), and Wex Medical Limited (“WML”). Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Na v 1.7 modulation program is intended to treat chronic and acute pain disorders. Our recently licensed SP16 program is centered on a cell signaling molecule that has shown early promise in treating neuropathy and nerve damage.
In its own words, from its 10-K, filed Mar 18, 2026.
Dogwood Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| DWTX Dogwood Therapeutics | Q3 2026 | $100K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Dogwood Therapeutics 10-Q on SEC EDGAR · CIK 1818844 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns DWTX and who is buying
More on DWTX
- How Dogwood Therapeutics makes money: revenue by segment
- Dogwood Therapeutics next earnings date and what analysts expect
- Dogwood Therapeutics stock forecast, price target and fair value
- Who owns Dogwood Therapeutics stock: holders, funds and Congress trades
- Dogwood Therapeutics guidance and outlook
- Dogwood Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results